EMA's restructured fee model may increase overall burden on drug firms
This article was originally published in Scrip
The European Medicines Agency is planning to restructure its current fee model so that there is "greater balance" between the money paid by pharmaceutical companies and the level of services provided by the agency. The proposed model, if approved, would effectively do away with the "tailor-made" approach currently being used – a move that has drawn major industry concern as it could increase the overall fee burden on drug companies.
You may also be interested in...
A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.
A damning UK report makes uncomfortable reading about how thousands of women suffered avoidable harm from the anti-epileptic drug sodium valproate and two other medical interventions and how safety concerns raised were dismissed, overlooked and ignored.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.